Yin Wen-Jin, Lu Jin-Song, Di Gen-Hong, Lin Yan-Ping, Zhou Li-Heng, Liu Guang-Yu, Wu Jiong, Shen Kun-Wei, Han Qi-Xia, Shen Zhen-Zhou, Shao Zhi-Ming
Department of Breast Surgery, Breast Cancer Institute, Cancer Hospital/Cancer Institute, Fudan University, 399 Ling-Ling Road, Shanghai 200032, People's Republic of China.
Breast Cancer Res Treat. 2009 May;115(2):325-33. doi: 10.1007/s10549-008-0096-0. Epub 2008 Jun 18.
In order to analyze the clinicopathological features of Chinese triple negative tumors, we performed a retrospective study of 1993 female unilateral breast cancer patients undergoing surgery in Cancer Hospital of Fudan University, Shanghai, China. Survival curves were performed with Kaplan-Meier method and annual recurrence hazard was estimated by hazard function. We observed that the rate of larger tumors in triple negative patients was higher than that in HR+/ERBB2- women, but lower than that in ERBB2+ subgroup (P = 0.0001). In addition, 21.83% of triple negative patients had four or more axillary lymph nodes involved as compared to 27.40% of ERBB2+ women and 22.75% of HR+/ERBB2- subgroup (P = 0.0056). In the survival analysis, we found a statistical significance for recurrence-free survival (RFS) among the three subgroups (P = 0.0037), with the rate of 72.89% for ERBB2+ patients, 78.40% for HR+/ERBB2- ones and 75.76% for triple negative ones at the 11th year respectively. When it came to hazard peaks, discrepancies existed in different subgroups. Similar to HR+/ERBB2- patients, triple negative subgroup showed an early major recurrence surge peaking at approximately year 2.5 as opposed to ERBB2+ counterparts with a tapering sharp at the 1st year. Furthermore, the first peak of triple negative tumors was higher than that of HR+/ERBB2- patients, but lower than that of ERBB2+ ones. Therefore, our findings suggested biological characteristics and prognostic outlook of Chinese triple negative breast cancers might be more favorable and somewhat different from those in Western populations.
为分析中国三阴性肿瘤的临床病理特征，我们对1993例在中国上海复旦大学附属肿瘤医院接受手术的女性单侧乳腺癌患者进行了一项回顾性研究。采用Kaplan-Meier法绘制生存曲线，并通过风险函数估计年度复发风险。我们观察到，三阴性患者中较大肿瘤的发生率高于HR+/ERBB2-女性，但低于ERBB2+亚组（P = 0.0001）。此外，21.83%的三阴性患者有四个或更多腋窝淋巴结受累，而ERBB2+女性为27.40%，HR+/ERBB2-亚组为22.75%（P = 0.0056）。在生存分析中，我们发现三个亚组之间的无复发生存期（RFS）具有统计学意义（P = 0.0037），在第11年时，ERBB2+患者的生存率为72.89%，HR+/ERBB2-患者为78.40%，三阴性患者为75.76%。在风险峰值方面，不同亚组存在差异。与HR+/ERBB2-患者相似，三阴性亚组在大约2.5年时出现早期主要复发高峰，而ERBB2+亚组在第1年时急剧下降。此外，三阴性肿瘤的第一个峰值高于HR+/ERBB2-患者，但低于ERBB2+患者。因此，我们的研究结果表明，中国三阴性乳腺癌的生物学特征和预后可能更有利，且与西方人群有所不同。
